STAT+: Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock
And so, another working week will soon draw to a close. Not a moment too…
Category: Pharma
STAT+: Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots
Good morning and congrats if you caught the “ring of fire” some of us in…
STAT+: WTO members agree to step up talks about Covid-19 intellectual property proposals
In what is being described as a “major breakthrough,” a World Trade Organization council agreed…
STAT+: Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows
WASHINGTON — Seventy-two senators and 302 members of the House of Representatives cashed a check…
Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds
WASHINGTON — State lawmakers in Oregon have tried to lower high drug prices from nearly…
STAT+: Regeneron shareholders urged to boot board member over executive pay practices
Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove the board…
STAT+: Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: ‘The price is bewildering’:The price of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks
The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen…
Opinion: FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs
The Food and Drug Administration yanked the fight against Alzheimer’s out of the mire with…
STAT+: Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells…
STAT+: EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’
Amid intense debate over equitable access to Covid-19 vaccines, the European Union is offering a…
STAT+: Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care
Come Monday, we should learn whether the Food and Drug Administration will approve the first…
STAT+: Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’
Martin Shkreli’s drug company has a lot of problems. Revenue was cut in half last…
STAT+: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer
Merck said Thursday that giving its drug Keytruda immediately after surgery significantly reduced the risk…
STAT+: AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning
Lynparza, a cancer-fighting pill marketed by AstraZeneca and Merck, reduced the risk that breast cancer…
STAT+: After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug…
STAT+: Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval
A lymphoma drug that was approved later than expected by regulators is at the center…
STAT+: Pharmalittle: Purdue bankruptcy plan clears a major hurdle; Senate Finance chair probes AbbVie over taxes
Good morning, everyone, and how are you today? A spot of rain, and then some,…
STAT+: Senate finance chair investigates AbbVie over its corporate tax strategy
AbbVie, which is already being probed by congressional Democrats for its pricing practices, is now…
STAT+: The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price
When Amber Freed heard in 2020 that a drug might help save her young child…
STAT+: Industry payments to doctors are associated with increased prescribing of long-acting insulin
Amid ongoing concern over the cost of insulin, a new study finds that payments made…
STAT+: Pharmalittle: JAMA editor stepping down after podcast furor; global agencies urge $50 billion investment to fight Covid-19
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?
In response to Congressional concerns over prescription drug pricing, the Federal Trade Commission released a…
‘A perilous point’: Global agencies call for $50 billion investment to combat Covid-19
In a plea to halt the Covid-19 pandemic, four global agencies are calling for investments…
STAT+: Pharmalittle: Biden in no rush to allow drug imports from Canada; deal on Covid-19 IP waiver remains elusive
Hello, everyone, and nice to see you again after taking an extended weekend break. Nothing…
STAT+: Pharmalittle: How Pfizer’s Covid vaccine boxes complicated rollout; FDA and J&J near deal to reopen vaccine plant
Good morning! Elizabeth Cooney sitting in for Ed Silverman today as he gets an early…
STAT+: Boxed in: How a single Pfizer decision disrupted the Covid vaccine rollout while boosting profits
Pfizer Covid-19 vaccines arrive in an insulated box, tightly packed with dry ice, roughly double…
STAT+: FDA revives a controversial program the Trump administration ended over ‘inaccuracies’
In an unexpected move, the Food and Drug Administration is reversing a decision by the…
STAT+: Pharmalittle: FDA authorizes another Covid-19 treatment; judge indicates Purdue reorganization plan can be voted on
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: Vaccine makers urge Biden to end support of Covid-19 IP waiver; Russia accused of sowing doubt over Pfizer shot
Rise and shine, everyone, the middle of the week is here. You made it this…
STAT+: In a possible sign of transparency, more leading universities are reporting clinical trial results
Over the past two years, many major U.S. universities have done a better job of…
STAT+: What deadline? Most clinical trials are still not reported on time to federal database
Amid ongoing calls for greater clinical trial transparency, a new analysis finds just 40% of…
STAT+: Pharmalittle: Moderna Covid-19 vaccine is effective in adolescents; U.S. lawmakers pitch a bill to create ‘biobonds’
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Lawmakers pitch a bill to create $30 billion in ‘biobonds’ to jumpstart drug development
In a bid to jumpstart drug development, a bipartisan group of lawmakers introduced a bill…
STAT+: European regulatory body plans ‘joint action’ to bolster clinical trial reporting
The Heads of Medicines Agencies, an umbrella group for regulators in 30 European Union countries,…
STAT+: Pharmalittle: BARDA lacks cash to invest in new Covid-19 drug development; AstraZeneca CEO hits back at European Commission
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Wealthy nations and drug makers offer moves to bridge Covid-19 vaccine divide
The leaders of the world’s wealthiest nations and several drug makers took steps to widen…
STAT+: Pharmalittle: Pfizer and India spar over indemnity for Covid-19 vaccines; J&J to supply Gavi with Covid shots
And so, another working week will soon draw to a close. Not a moment too…
‘There’s so much uncertainty’: As Mallinckrodt sells rare disease drug, parents worry about access
As it looks to emerge from bankruptcy, Mallinckrodt (MNK) has sold an experimental medicine that…
STAT+: Pharmalittle: Iovance CEO resigns amid a regulatory delay; Republican lawmakers urge Biden to reject Covid-19 IP waiver
Hello, everyone, and how are you today? The sun is shining brightly this morning on…
Opinion: Restore a better balance to public-private funding of biomedical research
The pharmaceutical industry says that if the U.S. reduces the astronomical drug prices paid by…
STAT+: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease
When doctors prescribe a personalized cell therapy today, the patient they’re trying to help has…
STAT+: What’s in a name? Spark Therapeutics sues Bluebird Bio over the use of the word ‘spark’
A promotional campaign has sparked a legal dispute between Spark Therapeutics and Bluebird Bio (BLUE)…
STAT+: Republican lawmakers tell Biden to reverse ‘disastrous decision’ to support Covid-19 IP waiver
Amid a furious debate over boosting global distribution of Covid-19 vaccines, more than a dozen…
STAT+: Fewer state Medicaid programs are restricting access to hepatitis C medicines, but hurdles remain
Over the past few years, state Medicaid programs have done a better job of disclosing…
STAT+: Emergent was aware of vaccine manufacturing issues even as it collected $27 million a month from U.S.
Under a contract awarded by the Trump administration, Emergent BioSolutions (EBS) was paid $27 million…
STAT+: Pharmalittle: Emergent to be grilled by some House members who received donations; lawmakers ask FTC to probe AbbVie
Rise and shine, everyone, another busy day, and especially so here on the Pharmalot campus,…